Cyclerion Therapeutics’ Licensing Agreement With Akebia Therapeutics

Morgan Lewis represented Cyclerion Therapeutics in the transaction.

Cyclerion Therapeutics Inc. closed a licensing agreement with Akebia Therapeutics Inc. for the development and commercialization of praliciguat, an oral soluble guanylate cyclase (sGC) stimulator.

Under the terms of the agreement, Akebia has obtained an exclusive license to research, develop and commercialize praliciguat globally and will be solely responsible for these activities going forward. Cyclerion is eligible to receive up to $225M in pre-commercial milestones, including up to $15M in the first 18 months. Total potential future development, regulatory, and commercialization milestone payments could result in up to $585M. Cyclerion is also eligible to receive tiered, sales-based royalties ranging from single-digit to high-teen percentages.

Cyclerion is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.

Akebia is a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Morgan Lewis represented Cyclerion with partner Suzanne Filippi (Picture) and associate Andrew Haupt.

Involved fees earner: Suzanne Filippi – Morgan Lewis & Bockius; Andrew Haupt – Morgan Lewis & Bockius;

Law Firms: Morgan Lewis & Bockius;

Clients: Cyclerion Therapeutics;

Author: Martina Bellini